Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.

Friberg TR, Tolentino M; LEVEL Study Group., Weber P, Patel S, Campbell S, Goldbaum M.

Br J Ophthalmol. 2010 Dec;94(12):1611-7. doi: 10.1136/bjo.2009.174946. Epub 2010 May 14.

2.

Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration.

Inoue M, Kadonosono K, Arakawa A, Yamane S, Ishibashi T.

Jpn J Ophthalmol. 2015 May;59(3):173-8. doi: 10.1007/s10384-015-0374-4. Epub 2015 Mar 4.

PMID:
25733493
3.

Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study).

Ishibashi T; LEVEL-J Study Group..

Jpn J Ophthalmol. 2013 Sep;57(5):417-23. doi: 10.1007/s10384-013-0255-7. Epub 2013 Jul 17.

PMID:
23860781
4.

Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.

Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.

Ophthalmology. 2008 Feb;115(2):347-354.e2. Epub 2007 Jul 12.

PMID:
17628685
5.

Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.

Quiram PA, Hassan TS, Williams GA.

Retina. 2007 Sep;27(7):851-6.

PMID:
17891008
6.

One-year outcomes of less frequent bevacizumab in age-related macular degeneration.

Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.

Retina. 2011 Apr;31(4):645-53. doi: 10.1097/IAE.0b013e3182012d18.

PMID:
21358363
7.

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group., Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.

PMID:
16828500
8.

VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Krishnan R, Arora R, De Salvo G, Stinghe A, Severn PS, Pal B, Goverdhan S.

Retina. 2015 Sep;35(9):1750-6. doi: 10.1097/IAE.0000000000000714.

PMID:
26237240
9.

Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration.

Emerson GG, Flaxel CJ, Lauer AK, Stout JT, Emerson MV, Nolte S, Wilson DJ, Klein ML.

Retina. 2007 Jul-Aug;27(6):724-9.

PMID:
17621181
10.

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.

11.

Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M.

Ophthalmology. 2014 Jan;121(1):188-92. doi: 10.1016/j.ophtha.2013.08.035. Epub 2013 Oct 18.

PMID:
24144450
12.

Bevacizumab for neovascular age-related macular degeneration in China.

Li X, Hu Y, Sun X, Zhang J, Zhang M; Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB)..

Ophthalmology. 2012 Oct;119(10):2087-93. doi: 10.1016/j.ophtha.2012.05.016. Epub 2012 Jul 20.

PMID:
22818896
13.

[Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].

Studnička J, Rencová E, Dusová J, Marák J, Burova M, Rozsíval P, Jarkovský J, Kandrnal V.

Cesk Slov Oftalmol. 2013 Aug;69(3):96-101. Czech.

PMID:
24437955
14.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

15.

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.

Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.

Ophthalmology. 2016 Mar;123(3):617-24. doi: 10.1016/j.ophtha.2015.10.039. Epub 2015 Dec 11.

PMID:
26686967
16.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126
17.

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group..

Ophthalmology. 2015 Dec;122(12):2514-22. doi: 10.1016/j.ophtha.2015.08.009. Epub 2015 Sep 29.

18.
19.

Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.

Marsiglia M, Boddu S, Chen CY, Jung JJ, Mrejen S, Gallego-Pinazo R, Freund KB.

Retina. 2015 May;35(5):966-74. doi: 10.1097/IAE.0000000000000460.

PMID:
25627089
20.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group..

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717

Supplemental Content

Support Center